U.S. Department of Health & Human Services
National Institutes of Health
NCATS
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
ANTITHROMBIN ALFA
AWV6I5L6H2
Possibly Marketed Outside US
First approved in 2009
General
Record Details
Variant Concepts
1
Names
7
Classification
5
Identifiers
12
Subunits
1
Disulfide Links
3
Glycosylation
4
Relationships
1
Active Moiety
1
Characteristic Attributes
2
ANTITHROMBIN ALFA
AWV6I5L6H2
Possibly Marketed Outside US
First approved in 2009
General
Approval Year
2009
359
Record Details
Substance Class
Protein
Protein Sub Type
Sequence Type
COMPLETE
Record UNII
AWV6I5L6H2
Record Status
Validated (UNII)
Record Version
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
Show
5
20
100
All
entries
Related Record
Type
Related Record
Type
No data available in table
Showing 0 to 0 of 0 entries
Previous
Next
Names
7
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
ANTITHROMBIN ALFA
Official Name
English
ANTITHROMBIN ALFA [USAN]
Common Name
English
ANTITHROMBIN ALFA [EMA EPAR]
Common Name
English
antithrombin alfa [INN]
Common Name
English
ANTITHROMBIN ALFA [MART.]
Common Name
English
Showing 1 to 5 of 7 entries
Previous
1
2
Next
Classification
5
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Agent Affecting Blood or Body Fluid
Pharmacologic Substance
[C1909]
Agent Affecting Blood or Body Fluid
[C78275]
Anticoagulant Agent
NCI_THESAURUS
C263
Designated/Approved
ORPHAN DRUG
Designated/Approved
Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures
FDA ORPHAN DRUG
246807
BLOOD COAGULATION DISORDERS, INHERITED
EMA EPAR
DISEASES
BLOOD AND LYMPHATIC DISEASES
HEMATOLOGIC DISEASES
BLOOD COAGULATION DISORDERS
BLOOD COAGULATION DISORDERS, INHERITED
ANTITHROMBIN III DEFICIENCY
EMA ASSESSMENT REPORTS
ATRYN (AUTHORIZED: ANTITHROMBIN III DEFICIENCY)
Designated
ORPHAN DRUG
Designated
Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.
FDA ORPHAN DRUG
118798
Established Pharmacologic Class
Established Pharmacologic Class
[EPC]
Recombinant Antithrombin
[EPC]
NDF-RT
N0000184170
Showing 1 to 5 of 5 entries
Previous
1
Next
Identifiers
12
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
ChEMBL
CHEMBL1201554
PRIMARY
INN
8429
PRIMARY
FDA UNII
AWV6I5L6H2
PRIMARY
SMS_ID
100000087989
PRIMARY
CAS
84720-88-7
PRIMARY
Showing 1 to 5 of 12 entries
Previous
1
2
3
Next
Subunits
1
Subunit 0
>SUBUNIT_0
Disulfide Links
3
Show
5
20
100
All
entries
From
To
From
To
1_8
1_128
1_21
1_95
1_247
1_430
Showing 1 to 3 of 3 entries
Previous
1
Next
Glycosylation
4
Glycosylation Type
MAMMALIAN
Show
5
20
100
All
entries
Glycosylation Link Type
Site
Glycosylation Link Type
Site
N
1_96
N
1_135
N
1_155
N
1_192
Showing 1 to 4 of 4 entries
Previous
1
Next
Relationships
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
ANTITHROMBIN (RECOMBINANT)
SUB_CONCEPT->SUBSTANCE
Showing 1 to 1 of 1 entries
Previous
1
Next
Active Moiety
1
Show
5
20
100
All
entries
Related Record
Type
Details
Related Record
Type
Details
AWV6I5L6H2
ANTITHROMBIN ALFA
ACTIVE MOIETY
Showing 1 to 1 of 1 entries
Previous
1
Next
Characteristic Attributes
2
Show
5
20
100
All
entries
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Name
Property Type
Amount
Referenced Substance
Defining
Parameters
References
Molecular Formula
CHEMICAL
ESTIMATED
C2191H3437N583O660PS18
MOL_WEIGHT:NUMBER(CALCULATED)
CHEMICAL
ESTIMATED 49000 Da (average)
Showing 1 to 2 of 2 entries
Previous
1
Next
